Back to Search
Start Over
Anacetrapib as a potential cardioprotective strategy
Anacetrapib as a potential cardioprotective strategy
- Source :
- Drug Design, Development and Therapy
- Publication Year :
- 2017
- Publisher :
- Informa UK Limited, 2017.
-
Abstract
- Cholesteryl ester transfer protein (CETP) facilitates movement of esterified cholesterol between high-density lipoproteins (HDLs) and apolipoprotein B-containing lipoproteins. By virtue of their ability to raise HDL cholesterol and lower low-density lipoprotein cholesterol, pharmacological inhibitors of CETP have received considerable attention as potential new agents in cardiovascular prevention. While early studies of CETP inhibitors have demonstrated a lack of clinical efficacy and potential toxicity, development of the potent CETP inhibitor, anacetrapib, has moved forward, with emerging evidence suggesting a role in reducing cardiovascular events. The experience with anacetrapib and its potential for use in clinical practice are reviewed here.
- Subjects :
- Apolipoprotein B
Pharmaceutical Science
Review
030204 cardiovascular system & hematology
Pharmacology
Esterified cholesterol
lipids
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
cardiovascular disease
Anacetrapib
CETP
Drug Discovery
Cholesterylester transfer protein
Animals
Humans
Medicine
030212 general & internal medicine
CETP inhibitor
Oxazolidinones
Lipoprotein cholesterol
biology
Cholesterol
business.industry
Anticholesteremic Agents
Cholesterol Ester Transfer Proteins
carbohydrates (lipids)
chemistry
Cardiovascular Diseases
biology.protein
anacetrapib
lipids (amino acids, peptides, and proteins)
atherosclerosis
business
Subjects
Details
- ISSN :
- 11778881
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Drug Design, Development and Therapy
- Accession number :
- edsair.doi.dedup.....e2c0768094f3b6a7109350e629897507
- Full Text :
- https://doi.org/10.2147/dddt.s114104